OBJECTIVE

To report on interim analysis of pain-related outcomes in subjects receiving injections of onabotulinumtoxinA as part of the ongoing CD-PROBE clinical registry.

METHODS

CD-PROBE is a prospective, open-label, multi-center, clinical registry for subjects treated for CD. Physicians differ in the care of patients and in the application of neurotoxin injection for CD. Neurotoxin injection for CD has been utilized worldwide for more than 20 years. OnabotulinumtoxinA (BOTOX® Allergan Inc.) was the first neurotoxin approved by the US Food and Drug Administration for the treatment of CD. Neurotoxin injection is accepted as first line treatment for CD. Pain associated with CD can lead to missed work and difficulties with activities of daily living. Exclusion criteria:

1. Subjects with CD appropriate for neurotoxin therapy
2. Pregnancy or nursing, or a planned pregnancy during the study
3. Poor compliance with past treatment plans
4. Subjects with CD who have previously participated in the CD-PROBE registry
5. Subjects with CD receiving steroid injections
6. Subjects with CD associated with myasthenia gravis
7. Subjects with CD with a history of metabolic disorders
8. Subjects with CD with a history of malignancy
9. Subjects with CD with a history of infection
10. Subjects with CD with a history of surgery
11. Subjects with CD with a history of trauma
12. Subjects with CD with a history of allergic reactions

RESULTS

CD-PROBE Study Group

The majority of subjects with CD reported pain. The pain associated with CD was significantly correlated with onabotulinumtoxinA injection, as measured on 3 separate scales. There was a significant correlation of 3 measures used to assess pain baseline: TWSTRS pain subscale, P-AUSc pain subscale, and CDIP-58 pain subscale. Additional information concerning the improvement of CD-associated pain relief following neurotoxin injection will become available as more subjects enroll in CD-PROBE.

REFERENCES


Presented at the 63rd Annual Meeting of the American Academy of Neurology, 9–16 April, 2011, Honolulu, Hawaii, USA.